Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.
Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Eleutherakis-Papaiakovou E, Fotiou D, Kanellias N, Dialoupi I, Makris N, Manios E, Migkou M, Roussou M, Kotsopoulou M, Stellos K, Terpos E, Trougakos IP, Stamatelopoulos K, Dimopoulos MA. Kastritis E, et al. Among authors: dialoupi i. Leukemia. 2021 May;35(5):1418-1427. doi: 10.1038/s41375-021-01141-4. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589757 Clinical Trial.
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: dialoupi i. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):23-28. doi: 10.1016/j.clml.2018.07.294. Epub 2018 Aug 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30224328
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dialoupi i. Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20. Amyloid. 2018. PMID: 30663408
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dialoupi i. Blood Adv. 2019 Oct 22;3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147. Blood Adv. 2019. PMID: 31648323 Free PMC article.
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsirigotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dialoupi i. Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539. Blood Adv. 2019. PMID: 31821457 Free PMC article.
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Malandrakis P, Eleutherakis-Papaiakovou E, Papatheodorou A, Kanellias N, Migkou M, Fotiou D, Dialoupi I, Roussou M, Kokkali NA, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: dialoupi i. Blood Cancer J. 2020 Mar 2;10(3):25. doi: 10.1038/s41408-020-0297-2. Blood Cancer J. 2020. PMID: 32123158 Free PMC article. No abstract available.
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Dialoupi I, Malandrakis P, Theodorakakou F, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: dialoupi i. Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647800 Free PMC article. No abstract available.
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, Eleutherakis-Papaiakovou E, Ntanasis-Stathopoulos I, Gakiopoulou C, Papanikolaou A, Papathoma A, Spyropoulou-Vlachou M, Psimenou E, Stamatelopoulos K, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dialoupi i. Amyloid. 2021 Mar;28(1):3-11. doi: 10.1080/13506129.2020.1798224. Epub 2020 Jul 27. Amyloid. 2021. PMID: 32713209
19 results